Search

Your search keyword '"Ricciarelli E"' showing total 41 results
Start Over Author "Ricciarelli E"
41 results on '"Ricciarelli E"'

1. A hybrid artificial intelligence model leverages multi-centric clinical data to improve fetal heart rate pregnancy prediction across time-lapse systems

Author

Duval, A, primary, Nogueira, D, additional, Dissler, N, additional, Maskani Filali, M, additional, Delestro Matos, F, additional, Chansel-Debordeaux, L, additional, Ferrer-Buitrago, M, additional, Ferrer, E, additional, Antequera, V, additional, Ruiz-Jorro, M, additional, Papaxanthos, A, additional, Ouchchane, H, additional, Keppi, B, additional, Prima, P-Y, additional, Regnier-Vigouroux, G, additional, Trebesses, L, additional, Geoffroy-Siraudin, C, additional, Zaragoza, S, additional, Scalici, E, additional, Sanguinet, P, additional, Cassagnard, N, additional, Ozanon, C, additional, De La Fuente, A, additional, Gómez, E, additional, Gervoise Boyer, M, additional, Boyer, P, additional, Ricciarelli, E, additional, Pollet-Villard, X, additional, and Boussommier-Calleja, A, additional

Published
2023
Full Text
View/download PDF

6. Reply:GnRH agonist for triggering final oocyte maturation: Time for a critical evaluation of data

Author

Humaidan, P., Kol, S., Benadiva, C., Engmann, L., Papanikolaou, E. G., Itskovitz-Eldor, J., Margalioth, E. J., Ricciarelli, E., Bodri, D., Castillo-Farfan, J. C., Garcia-Velasco, J. A., Yding Andersen, C., Devroey, P., and Tarlatzis, B.

Subjects
Agonist, medicine.medical_specialty, Endocrinology, medicine.anatomical_structure, Reproductive Medicine, business.industry, medicine.drug_class, Internal medicine, Obstetrics and Gynecology, Medicine, business, Oocyte
Published
2012
Full Text
View/download PDF

8. Psychology and counselling

Author

Van Parys, H., primary, Wyverkens, E., additional, Provoost, V., additional, Ravelingien, A., additional, Raes, I., additional, Somers, S., additional, Stuyver, I., additional, De Sutter, P., additional, Pennings, G., additional, Buysse, A., additional, Anttila, V. S., additional, Salevaara, M., additional, Suikkari, A. M., additional, Listijono, D. R., additional, Mooney, S., additional, Chapman, M. G., additional, Res Muravec, U., additional, Pusica, S., additional, Lomsek, M., additional, Cizek Sajko, M., additional, Parames, S., additional, Semiao-Francisco, L., additional, Sato, H., additional, Ueno, J., additional, van den Wijngaard, L., additional, Mochtar, M. H., additional, van Dam, H., additional, van der Veen, F., additional, van Wely, M., additional, Derks-Smeets, I. A. P., additional, Habets, J. J. G., additional, Tibben, A., additional, Tjan-Heijnen, V. C. G., additional, Meijer-Hoogeveen, M., additional, Geraedts, J. P. M., additional, van Golde, R., additional, Gomez-Garcia, E., additional, de Die-Smulders, C. E. M., additional, van Osch, L. A. D. M., additional, Kets, C. M., additional, Gullo, S., additional, Donarelli, Z., additional, Coco, G. L., additional, Marino, A., additional, Volpes, A., additional, Sammartano, F., additional, Allegra, A., additional, Nekkebroeck, J., additional, Tournaye, H., additional, Stoop, D., additional, Lo Coco, G., additional, Coffaro, F., additional, Diaz, D. G., additional, Gonzalez, M. A., additional, Tirado, M., additional, Chamorro, S., additional, Dolz, P., additional, Gil, M. A., additional, Ballesteros, A., additional, Velilla, E., additional, Castello, C., additional, Moina, N., additional, Lopez-Teijon, M., additional, Chan, C. H. Y., additional, Chan, C. L. W., additional, Leong, M. K. H., additional, Cheung, I. K. M., additional, Chan, T. H. Y., additional, Hui, B. N. L., additional, van Dongen, A. J. C. M., additional, Huppelschoten, A. G., additional, Kremer, J. A. M., additional, Nelen, W. L. D. M., additional, Verhaak, C. M., additional, Sun, H. G., additional, Lee, K. H., additional, Park, I. H., additional, Kim, S. G., additional, Lee, J. H., additional, Kim, Y. Y., additional, Kim, H. J., additional, Cho, J. D., additional, Yoo, Y. J., additional, Frokjaer, V., additional, Pinborg, A., additional, Larsen, E. C., additional, Heede, M., additional, Stenbaek, D. S., additional, Henningsson, S., additional, Nielsen, A. P., additional, Svarer, C., additional, Holst, K. K., additional, Knudsen, G. M., additional, Emery, M., additional, DeJonckheere, L., additional, Rothen, S., additional, Wisard, M., additional, Germond, M., additional, Toftager, M., additional, Hjordt, L. V., additional, Jensen, P. S., additional, Holst, K., additional, Holland, T., additional, Bryndorf, T., additional, Bogstad, J., additional, Hornnes, P., additional, Frokjaer, V. G., additional, Dornelles, L. M. N., additional, MacCallum, F., additional, Lopes, R. C. S., additional, Piccinini, C. A., additional, Passos, E. P., additional, Bruegge, C., additional, Thorn, P., additional, Daniels, K., additional, Imrie, S., additional, Jadva, V., additional, Golombok, S., additional, Arens, Y., additional, De Krom, G., additional, Van Golde, R. J. T., additional, Coonen, E., additional, Van Ravenswaaij-Arts, C. M. A., additional, Evers, J. L. H., additional, De Die-Smulders, C. E. M., additional, Ghazeeri, G., additional, Awwad, J., additional, Fakih, A., additional, Abbas, H., additional, Harajly, S., additional, Tawidian, L., additional, Maalouf, F., additional, Ajdukovic, D., additional, Pibernik-Okanovic, M., additional, Alebic, M. S., additional, Baccino, G., additional, Calatayud, C., additional, Ricciarelli, E., additional, de Miguel, E. R. H., additional, Wierckx, K., additional, Verstraelen, H., additional, Van Glabeke, L., additional, Van den Abbeel, E., additional, Gerris, J., additional, T'Sjoen, G., additional, Monica, B., additional, Calonge, R. N., additional, Peregrin, P. C., additional, Cserepes, R., additional, Kollar, J., additional, Wischmann, T., additional, Bugan, A., additional, Pinkard, C., additional, Harrison, C., additional, Bunting, L., additional, Boivin, J., additional, Fulford, B., additional, Theusink-Kirchhoff, N., additional, van Ravenswaaij-Arts, C. M. A., additional, Bakker, M. K., additional, Volks, C., additional, Papaligoura, Z., additional, Papadatou, D., additional, Bellali, T. H., additional, Jarvholm, S., additional, Broberg, M., additional, Thurin-Kjellberg, A., additional, Weitzman, G., additional, Van Der Putten-Landau, T. M., additional, Chudnoff, S., additional, Panagopoulou, E., additional, Tarlatzis, B., additional, Tamhankar, V., additional, Jones, G. L., additional, Magill, P., additional, Skull, J. D., additional, Ledger, W., additional, Hvidman, H. W., additional, Specht, I. O., additional, Schmidt, K. T., additional, Andersen, A. N., additional, Freeman, T., additional, Zadeh, S., additional, Smith, V., additional, Whitaker, L. H. R., additional, Reid, J., additional, Wilson, J., additional, Critchley, H. O. D., additional, Horne, A. W., additional, Peterson, B., additional, Pirritano, M., additional, Schmidt, L., additional, Volgsten, H., additional, Van Parys, H., additional, Hudson, N., additional, Culley, L., additional, Law, C., additional, Denny, E., additional, Mitchell, H., additional, Baumgarten, M., additional, Raine-Fenning, N., additional, Blake, L., additional, and Kim, K. H., additional

Published
2013
Full Text
View/download PDF

9. QUALITY AND SAFETY OF ART THERAPIES

Author

Caballero, P., primary, Alonso, J., additional, Cortes, S., additional, Caballero Campo, M., additional, Gago, M., additional, Nunez-Calonge, R., additional, Ricciarelli, E., additional, Gomez Palomares, J. L., additional, Bruna Catalan, I., additional, Hernandez, E. R., additional, Grzegorczyk-Martin, V., additional, Belaisch-Allart, J., additional, Mayenga, J. M., additional, Kulski, O., additional, Plachot, M., additional, Darby, H. C., additional, Florensa Bargallo, M., additional, Perals Vazquez, N., additional, Esbert Algam, M., additional, Belles Fernandez, M., additional, Ballesteros Boluda, A., additional, Calderon de Oya, G., additional, Alegre de Miquel, M., additional, Choudhary, M., additional, Ramineni, A., additional, Stewart, J., additional, Cabello, Y., additional, Fernandez-Shaw, S., additional, Mercader, A., additional, Herrer, R., additional, Arroyo, G., additional, Del Rio, F., additional, Carrera, M., additional, Fernandez Sanchez, M., additional, Sumimoto, T., additional, Kataoka, N., additional, Ogata, H., additional, Mizuta, S., additional, Tokura, Y., additional, Yamada, S., additional, Ogata, S., additional, Mizusawa, Y., additional, Matsumoto, Y., additional, Okamoto, E., additional, Kokeguchi, S., additional, Shiotani, M., additional, Nagai, Y., additional, Otsuki, J., additional, Maeda, K., additional, Momma, Y., additional, Takahashi, K., additional, Chuko, M., additional, Miwa, A., additional, Nagai, A., additional, Seggers, J., additional, Haadsma, M. L., additional, La Bastide-van Gemert, S., additional, Heineman, M. J., additional, Kok, J. H., additional, Middelburg, K. J., additional, Roseboom, T. J., additional, Schendelaar, P., additional, Van den Heuvel, E. R., additional, Hadders-Algra, M., additional, Jongbloed-Pereboom, M., additional, La Bastide-Van Gemert, S., additional, Heineman, K. R., additional, Bos, A. F., additional, Kondapalli, L. A., additional, Shaunik, A., additional, Molinaro, T. A., additional, Ratcliffe, S. J., additional, Barnhart, K. T., additional, Haadsma, M., additional, Keating, P., additional, Van Hoften, J. C., additional, Veenstra-Knol, H. E., additional, Cobben, J. M., additional, Pirkevi, C., additional, Atayurt, Z., additional, Yelke, H., additional, Kahraman, S., additional, Desmyttere, S., additional, Verpoest, W., additional, Haentjens, P., additional, Verheyen, G., additional, Liebaers, I., additional, Bonduelle, M., additional, Winter, C., additional, Van Acker, F., additional, De Schrijver, F., additional, Nekkebroeck, J., additional, Pariente-Khayat, A., additional, de Laubier, A., additional, Fehily, D., additional, Lemardeley, G., additional, Merlet, F., additional, Creusvaux, H., additional, Nakajo, Y., additional, Sakamoto, E., additional, Doshida, M., additional, Toya, M., additional, Nasu, I., additional, Kyono, K., additional, Schats, R., additional, Vergouw, C. G., additional, Kostelijk, E. H., additional, Doejaaren, E., additional, Hompes, P. G. A., additional, Lambalk, C. B., additional, Nakamura, Y., additional, Takisawa, T., additional, Shibuya, Y., additional, Sato, Y., additional, Sato, K., additional, Berard, A., additional, Chaabane, S., additional, Sheehy, O., additional, Blais, L., additional, Fraser, W., additional, Bissonnette, F., additional, Monnier, P., additional, Tan, S. L., additional, Trasler, J., additional, Subramaniam, A., additional, Chiappetta, R., additional, Mania, A., additional, Trew, G., additional, Lavery, S. A., additional, van den Akker, O., additional, Purewal, S., additional, Bunnell, C., additional, Lashen, H., additional, Terriou, P., additional, Giorgetti, C., additional, Porcu-Buisson, G., additional, Roger, V., additional, Chinchole, J. M., additional, Hamon, V., additional, Allemand-Sourieu, J., additional, Cravello, L., additional, Moreau, J., additional, Chabert-Orsini, V., additional, Belva, F., additional, Roelants, M., additional, De Schepper, J., additional, Devroey, P., additional, Painter, R. C., additional, Machin, L., additional, Fearon, K., additional, Morishima, K., additional, Fujimoto, A., additional, Oishi, H., additional, Hirata, T., additional, Harada, M., additional, Hasegawa, A., additional, Osuga, Y., additional, Yano, T., additional, Kozuma, S., additional, and Taketani, Y., additional

Published
2012
Full Text
View/download PDF

10. Posters * Safety & Quality (I.E. Guidelines, Multiple Pregnancy, Outcome, Follow-Up etc.)

Author

Ocal, P., primary, Sahmay, S., additional, Irez, T., additional, Senol, H., additional, Cepni, I., additional, Purisa, S., additional, Lin, W., additional, Liu, X., additional, Donjacour, A., additional, Maltepe, E., additional, Rinaudo, P., additional, Baumgarten, M. N., additional, Stoop, D., additional, Haentjes, P., additional, Verheyen, G., additional, De Schrijver, F., additional, Liebaers, I., additional, Camus, M., additional, Bonduelle, M., additional, Devroey, P., additional, Nelissen, E. C. M., additional, Van Montfoort, A. P. A., additional, Coonen, E., additional, Derhaag, J. G., additional, Evers, J. L. H., additional, Dumoulin, J. C. M., additional, Costa Lopes, J. R., additional, Mendes dos Santos, J., additional, Portugal Silva Lima, S., additional, Portugal Silva Souza, S., additional, Rodrigues Pereira, T., additional, Barguil Brasileiro, J. P., additional, Pina, H., additional, Lessa, M. L., additional, Genovese Soares, M., additional, Medina Lopes, V., additional, Ribeiro, C. G., additional, Adami, K., additional, Hughes, C., additional, Emerson, G., additional, Grundy, K., additional, Kelly, P., additional, Mocanu, E., additional, Coelho Cafe, T., additional, de Souza Costa, J. B. M., additional, Zavattiero Tierno, N. I., additional, Singh, S., additional, Vitthala, S., additional, Zosmer, A., additional, Sabatini, L., additional, Tozer, A., additional, Davis, C., additional, Al-Shawaf, T., additional, Neri, Q. V., additional, Monahan, D., additional, Rosenwaks, Z., additional, Palermo, G. D., additional, Kalu, E., additional, Thum, M. Y., additional, Abdalla, H. A., additional, Sazonova, A., additional, Bergh, C., additional, Kallen, K., additional, Thurin-Kjellberg, A., additional, Wennerholm, U. B., additional, Griesinger, G., additional, Doody, K., additional, Witjes, H., additional, Mannaerts, B., additional, Tarlatzis, B., additional, Rombauts, L., additional, Heijnen, E., additional, Marintcheva-Petrova, M., additional, Elbers, J., additional, Koning, A., additional, Mutsaerts, M. A. Q., additional, Hoek, A., additional, Mol, B. W., additional, Fadini, R., additional, Guarnieri, T., additional, Mignini Renzini, M., additional, Comi, R., additional, Mastrolilli, M., additional, Villa, A., additional, Colpi, E., additional, Coticchio, G., additional, Dal Canto, M., additional, Dolleman, M., additional, Broer, S. L., additional, Opmeer, B. C., additional, Fauser, B. C., additional, Broekmans, F. J. M., additional, Alama, P., additional, Requena, A., additional, Crespo, J., additional, Munoz, M., additional, Ballesteros, A., additional, Munoz, E., additional, Fernandez, M., additional, Meseguer, M., additional, Garcia-Velasco, J. A., additional, Pellicer, A., additional, Munk, M., additional, Smidt-Jensen, S., additional, Blaabjerg, J., additional, Christoffersen, C., additional, Lenz, S., additional, Lindenberg, S., additional, Bosch, E., additional, Labarta, E., additional, Cruz, F., additional, Simon, C., additional, Remohi, J., additional, Esler, J., additional, Osborn, J., additional, Boissonnas Chalas, C., additional, Marszalek, A., additional, Fauque, P., additional, Wolf, J. P., additional, De Ziegler, D., additional, Cabanes, L., additional, Jouannet, P., additional, Han, A. R., additional, Park, C. W., additional, Cha, S. W., additional, Kim, H. O., additional, Yang, K. M., additional, Kim, J. Y., additional, Song, I. O., additional, Koong, M. K., additional, Kang, I. S., additional, Roszaman, R., additional, Omar, M. H., additional, Nazri, Y., additional, Azantee, Y. W., additional, Murad, A. Z., additional, Zainulrashid, M. R., additional, Wang, N., additional, Le, F., additional, Wang, L. Y., additional, Ding, G. L., additional, Sheng, J. Z., additional, Huang, H. F., additional, Jin, F., additional, Reinblatt, S., additional, Holzer, H., additional, Son, W. Y., additional, Shalom-Paz, E., additional, Chian, R. C., additional, Buckett, W., additional, Dahan, M., additional, Demirtas, E., additional, Tan, S. L., additional, Revel, A., additional, Schejter-Dinur, Y., additional, Revel-Vilk, S., additional, Hermens, R. P. M. G., additional, van den Boogaard, E., additional, Leschot, N. J., additional, Vollebergh, J. H. A., additional, Bernardus, R., additional, Kremer, J. A. M., additional, van der Veen, F., additional, Goddijn, M., additional, Nahuis, M. J., additional, Kose, N., additional, Bayram, N., additional, Hompes, P. G. A., additional, Mol, B. W. J., additional, van der veen, F., additional, van Wely, M., additional, Van Disseldorp, J., additional, Dolleman, M. D., additional, Broeze, K., additional, De Rycke, M., additional, Petrussa, L., additional, Van de Velde, H., additional, Cerrillo, M., additional, Pacheco, A., additional, Rodriguez, S., additional, Gomez, R., additional, Delagado, F., additional, Garcia Velasco, J. A., additional, Desmyttere, S., additional, Verpoest, W., additional, Staessen, C., additional, De Vos, A., additional, Kohls, G., additional, Ruiz, F. J., additional, De la Fuente, G., additional, Toribio, M., additional, Martinez, M., additional, Soderstrom - Anttila, V., additional, Salevaara, M., additional, Suikkari, A. M., additional, Clua, E., additional, Tur, R., additional, Alcaniz, N., additional, Boada, M., additional, Rodriguez, I., additional, Barri, P. N., additional, Veiga, A., additional, Nelen, W. L. D. M., additional, Van Empel, I. W. H., additional, Cohlen, B. J., additional, Laven, J. S., additional, Aarts, J. W. M., additional, Ricciarelli, E., additional, Gomez-Palomares, J. L., additional, Andres-Criado, L., additional, Hernandez, E. R., additional, Courbiere, B., additional, Aye, M., additional, Perrin, J., additional, Di Giorgio, C., additional, De Meo, M., additional, Botta, A., additional, Castilla Alcala, J., additional, Luceno Maestre, F., additional, Cabello, Y., additional, Hernandez, J., additional, Marqueta, J., additional, Pareja, A., additional, Hernandez, E., additional, Coroleu, B., additional, Helmgaard, L., additional, Klein, B. M., additional, Arce, J. C., additional, van Empel, I. W. H., additional, Boivin, J., additional, Verhaak, C. M., additional, Ding, G., additional, Yin, R., additional, Sheng, J., additional, Huang, H., additional, Mancini, F., additional, Gomez, M. J., additional, van den Boogaard, N. M., additional, van der Steeg, J. W., additional, Hompes, P., additional, Boyer, P., additional, Gervoise-Boyer, M., additional, Meddeb, L., additional, Rossin, B., additional, Audibert, F., additional, Sakian, S., additional, Chan Wong, E., additional, Ma, S., additional, Pathak, R., additional, Mustafa, M. D., additional, Ahmed, R. S., additional, Tripathi, A. K., additional, Guleria, K., additional, Banerjee, B. D., additional, Vela, G., additional, Luna, M., additional, Flisser, E. D., additional, Sandler, B., additional, Brodman, M., additional, Grunfeld, L., additional, Copperman, A. B., additional, Baronio, M., additional, Carrascosa, P., additional, Capunay, C., additional, Vallejos, J., additional, Papier, S., additional, Borghi, M., additional, Sueldo, C., additional, Carrascosa, J., additional, Martin Lopez, E., additional, Marcucci, A., additional, Marcucci, I., additional, Salacone, P., additional, Sebastianelli, A., additional, Caponecchia, L., additional, Pacini, N., additional, Rago, R., additional, Alvarez, M., additional, Carreras, O., additional, Arnoldi, M., additional, Diaferia, D., additional, Corbucci, M. G., additional, De Lauretis, L., additional, Kook, M. J., additional, Jung, J. Y., additional, Lee, J. H., additional, Jung, Y. J., additional, Hwang, H. K., additional, Kang, A., additional, An, S. J., additional, Kim, H. M., additional, Kwon, H. C., additional, Lee, S. J., additional, Satoh, M., additional, Imada, J., additional, Ito, K., additional, Migishima, F., additional, Inoue, T., additional, Ohnishi, Y., additional, Kawato, H., additional, Nakaoka, Y., additional, Fukuda, A., additional, Morimoto, Y., additional, Mourad, S., additional, Grol, R. P. T. M., additional, Polyzos, N. P., additional, Valachis, A., additional, Patavoukas, E., additional, Papanikolaou, E. G., additional, Messinis, I. E., additional, Tarlatzis, B. C., additional, Kang, H., additional, Kim, C. H., additional, Park, E., additional, Kim, S., additional, Chae, H. D., additional, Kang, B. M., additional, Jung, K. S., additional, Song, H. J., additional, Ahn, Y. S., additional, Petkova, L., additional, Canov, I., additional, Milachich, T., additional, Shterev, A., additional, Patrat, C., additional, Pocate, K., additional, Juillard, J. C., additional, Gayet, V., additional, Blanchet, V., additional, de Ziegler, D., additional, van der, J. W., additional, Leushuis, E., additional, Steures, P., additional, Koks, C., additional, Oosterhuis, J., additional, Bourdrez, P., additional, and Bossuyt, P. M., additional

Published
2010
Full Text
View/download PDF

12. P-738

Author

Gomez-Palomares, J., primary, Acevedo-Martin, B., additional, Chavez, M., additional, Manzanares, M., additional, Hernandez, E.R., additional, and Ricciarelli, E., additional

Published
2006
Full Text
View/download PDF

21. Insulin-like growth factors: the ovarian connection.

Author

Adashi, E Y, Resnick, C E, Hurwitz, A, Ricciarelli, E, Hernandez, E R, Roberts, C T, Leroith, D, and Rosenfeld, R

Abstract

A large body of information now supports the existence of a complete intraovarian insulin-like growth factor (IGF) system replete with ligands, receptors, and binding proteins. Although much remains to be learned, the emerging consensus would suggest that the intraovarian IGF system is concerned largely with the amplification of gonadotrophin hormonal action for the facilitation of follicular growth and development. Future studies are likely to address the central issue of indispensability and the documentation of a meaningful in vivo role for this and related putative intraovarian regulators. [ABSTRACT FROM AUTHOR]

Published
1991

25. Evaluation of the effectiveness and clinical security of Menopur® in the ovarian stimulation in IVF-ICSI,Evaluación de la efectividad y seguridad clínica de Menopur® en la estimulación de la ovulación en ciclos de FIV-ICSI

Author

Requena, A., García-Velasco, J. A., Coroleu, B., Alarcón, M., Alberto-Bethencourt, J. C., Báez, D., Balasch, J., Bernabeu, R., Brassesco, M., Caballero-Peregrín, P., Calderón, M. A., Carrera, M., Cuadrado, C., Domingo, J., Elbaile, M., Fábregas, F., Manuel Fernández-Sánchez, Flóres, A., Fontes, J., Galera, F., García-Gimeno, T., Izquierdo, M., Landeras, J., Llácer, J., López-Teijón, M. L., Maldonado, V., Martínez Moya, M., Martínez Navarro, L., Monzó, A., Nadal, J., Polo, A., Remohí, J., Ricciarelli, E., Romeu, A., Ruiz-Balda, J. A., Sánchez, F., Sánchez, P., Serna, J., Viscasillas, P., González, E., Fernández-Nistal, A., Arias, E., Calvo-Tomero, S., Seco, C., and Martínez Fernández, V.

26. Erratum: Evaluation of the effectiveness and clinical security of Menopur® in the ovarian stimulation in IVF-ICSI (Revista Iberoamericana de Fertilidad y Reproduccion Humana)

Author

Requena, A., García-Velasco, J. A., Coroleu, B., Alarcón, M., Alberto-Bethencourt, J. C., Báez, D., Balasch, J., Bernabeu, R., Brassesco, M., Caballero-Peregrín, P., Calderón, M. A., Carranza, F. J., Carrera, M., Cuadrado, C., Domingo, J., Elbaile, M., Fábregas, F., Manuel Fernández-Sánchez, Flóres, A., Fontes, J., Galera, F., García-Gimeno, T., Izquierdo, M., Landeras, J., Llácer, J., López-Teijón, M. L., Maldonado, V., Martínez Moya, M., Martínez Navarro, L., Monzó, A., Nadal, J., Polo, A., Remohí, J., Ricciarelli, E., Romeu, A., Ruiz-Balda, J. A., Sánchez, F., Sánchez, P., Serna, J., Viscasillas, P., Gonzáles, E., Fernández-Nistal, A., Arias, E., Calvo-Tomero, S., Seco, C., and Martínez, V.

29. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.

Author

Manzanares MA, Gómez-Palomares JL, Ricciarelli E, and Hernández ER

Subjects
Adult, Estradiol biosynthesis, Female, Fertilization in Vitro adverse effects, Fertilization in Vitro methods, Follicle Stimulating Hormone adverse effects, Follicle Stimulating Hormone pharmacology, Follicle Stimulating Hormone therapeutic use, Gonadotropin-Releasing Hormone administration & dosage, Gonadotropin-Releasing Hormone analogs & derivatives, Humans, Ovarian Hyperstimulation Syndrome chemically induced, Polycystic Ovary Syndrome drug therapy, Pregnancy, Recombinant Proteins adverse effects, Recombinant Proteins pharmacology, Recombinant Proteins therapeutic use, Retrospective Studies, Estradiol blood, Gonadotropin-Releasing Hormone agonists, Gonadotropin-Releasing Hormone blood, Ovarian Hyperstimulation Syndrome blood, Ovulation Induction methods, Polycystic Ovary Syndrome blood
Abstract

Objective: To determine whether inducing ovulation with a GnRH agonist in patients with polycystic ovaries (PCO) would permit oocyte retrieval without the burden or risk of cancellation, coasting, or ovarian hyperstimulation syndrome (OHSS), thus maintaining pregnancy rates by allowing embryo cryopreservation for transfer in a subsequent cycle., Design: Retrospective observational study., Setting: Private institution., Patient(s): Forty-two women who had previously experienced a controlled ovarian hyperstimulation (COH)/IVF cycle that had to be cancelled because of an elevated risk of OHSS., Intervention(s): Forty-two PCO patients with a previous cancelled IVF cycle were assigned to a second controlled ovarian stimulation with recombinant FSH (75-150 IU/day) + GnRH antagonist (0.25 mg/day). Embryos were cryopreserved and transferred in a later cycle., Main Outcome Measure(s): OHSS, oocyte retrieval, and pregnancy rates., Result(s): In the first COH, the cycle had to be cancelled to avoid OHSS because E(2) serum levels were above safety levels (4809.6 +/- 2947.7). However, in the second cycle (ovulation triggered with a GnRH agonist) and independent of E(2) serum levels (4518.5 +/- 2118.85), all PCO patients eventually completed oocyte retrieval and frozen ET. With regard to pregnancy rates, 33% of patients receiving a transfer of a previously frozen embryo were successful. No patient developed OHSS., Conclusion(s): Triggering ovulation with a GnRH agonist followed by embryo cryopreservation allows PCO patients to complete a COH/IVF cycle with no cycle cancellation, coasting, or OHSS and, finally, to attain good pregnancy rates., (Copyright 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.)

Published
2010
Full Text
View/download PDF

30. No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles.

Author

Hernández ER, Gómez-Palomares JL, and Ricciarelli E

Subjects
Adult, Chorionic Gonadotropin pharmacology, Dose-Response Relationship, Drug, Female, Gonadotropin-Releasing Hormone agonists, Humans, Luteolytic Agents adverse effects, Luteolytic Agents pharmacology, Oocyte Retrieval methods, Ovulation drug effects, Pregnancy, Pregnancy Rate, Reproductive Control Agents adverse effects, Reproductive Control Agents pharmacology, Retrospective Studies, Treatment Failure, Triptorelin Pamoate pharmacology, Chorionic Gonadotropin adverse effects, Fertilization in Vitro adverse effects, Fertilization in Vitro methods, Oocyte Donation adverse effects, Oocyte Donation methods, Ovarian Hyperstimulation Syndrome etiology, Triptorelin Pamoate adverse effects
Abstract

We retrospectively studied 429 IVF donor cycles in which ovulation was triggered with either hCG (175 cycles) or GnRH agonist (254 cycles). Of the donors in whom ovulation was triggered with hCG, 3.2% developed symptoms of moderate (2.2%) or severe (1%) ovarian hyperstimulation syndrome, while none of the IVF donor cycles that were triggered with the GnRH agonist presented ovarian hyperstimulation syndrome, needed coasting, or were cancelled.

Published
2009
Full Text
View/download PDF

31. Multifollicular recruitment in combination with gonadotropin-releasing hormone antagonist increased pregnancy rates in intrauterine insemination cycles.

Author

Gómez-Palomares JL, Acevedo-Martín B, Chávez M, Manzanares M, Ricciarelli E, and Hernández ER

Subjects
Adult, Chorionic Gonadotropin administration & dosage, Drug Administration Schedule, Drug Therapy, Combination, Female, Fertility Agents, Female administration & dosage, Follicle Stimulating Hormone therapeutic use, Gonadotropin-Releasing Hormone administration & dosage, Gonadotropin-Releasing Hormone metabolism, Gonadotropin-Releasing Hormone therapeutic use, Hormone Antagonists administration & dosage, Humans, Infertility, Female metabolism, Pregnancy, Pregnancy Rate, Prospective Studies, Recombinant Proteins therapeutic use, Treatment Outcome, Fertility Agents, Female therapeutic use, Gonadotropin-Releasing Hormone analogs & derivatives, Gonadotropin-Releasing Hormone antagonists & inhibitors, Hormone Antagonists therapeutic use, Infertility, Female therapy, Insemination, Artificial, Ovarian Follicle drug effects, Ovulation Induction
Abstract

Objective: To determine whether including a GnRH antagonist in controlled ovarian stimulation-intrauterine insemination cycles would increase pregnancy rates., Design: Prospective randomized study., Setting: Private reproductive medicine clinic in Spain., Patient(s): Three hundred sixty-seven women with primary or secondary infertility., Intervention(s): Patients were randomly assigned to controlled ovarian stimulation with recombinant FSH (75-150 IU/d) alone (controls, n = 183) or with recombinant FSH (75-150 IU/d) + the GnRH antagonist (0.25 mg/d), initiated when the recruited follicles were >or=16 mm (n = 184). A single insemination was performed, 36-38 hours after hCG (5,000 IU, IM), in both groups., Main Outcome Measure(s): Follicular recruitment, pregnancy rates., Result(s): Numbers of mature follicles (2.4 +/- 1.3 vs. 1.3 +/- 1.09) and clinical pregnancy rates (23% vs. 11%) were statistically significantly higher in patients who were treated with GnRH antagonist than in those who were in the control group. The pregnancy rate was only higher in the antagonist group if more than one follicle sized >or=18 mm was present on the day that the hCG was given. A similar number of twin pregnancies occurred in both groups: two in the antagonist group and three in the control group. The antagonist group also had one triplet gestation., Conclusion(s): Adding GnRH antagonist to controlled ovarian stimulation-intrauterine insemination cycles significantly increases pregnancy rates in multifollicular, but not monofollicular, cycles.

Published
2008
Full Text
View/download PDF

32. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates.

Author

Acevedo B, Gomez-Palomares JL, Ricciarelli E, and Hernández ER

Subjects
Adult, Female, Humans, Pregnancy, Treatment Outcome, Embryo Implantation drug effects, Fertilization in Vitro methods, Gonadotropin-Releasing Hormone agonists, Infertility, Female therapy, Ovulation Induction methods, Pregnancy Outcome, Triptorelin Pamoate administration & dosage
Abstract

Objective: To evaluate the implant capacity of embryos derived from oocytes matured with a bolus of GnRH agonist., Design: Donors were randomly assigned to a protocol using either GnRH agonist or recombinant (r) hCG to trigger ovulation. Analysis of variance, Student t test, and Fisher exact test were used where appropriate., Setting: Private clinical setting., Patient(s): Young voluntary donors receiving GnRH agonist (n = 30) or rhCG (n = 30). Eighty-nine patients received oocytes., Intervention(s): Controlled ovarian stimulation was carried out with GnRH antagonist and FSH/LH in a step-down protocol. Donors received a single bolus of GnRH agonist (0.2 mg) or rhCG (250 microg). The endometrial tissue of recipient patients was prepared with oral E(2) and P., Main Outcome Measure(s): Pregnancy and implantation rates and ovarian hyperstimulation syndrome (OHSS) in an IVF donor program., Result(s): No significant differences in the number of retrieved oocytes (327 vs. 288), MII oocytes (70% vs. 76%), fertilization (80% vs. 65%,), pregnancy/transfer (55% vs. 59%), and implantation rates (29% vs. 32%) were found between recipients whose embryos originated from donors in whom final oocyte maturation was triggered with GnRH agonist and those whose donors received hCG. Significant differences in luteal phase length (4.16 + 0.70 days vs. 13.63 + 2.12 days) and in OHSS (0/30 vs. 5/30) were seen between donors ovulated with the agonist and the donors in whom ovulation was triggered with hCG., Conclusion(s): In controlled ovarian stimulation IVF donor cycles, GnRH agonists trigger ovulation and induce luteolysis but do not compromise embryo implantation capacity.

Published
2006
Full Text
View/download PDF

33. Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles.

Author

Acevedo B, Sanchez M, Gomez JL, Cuadros J, Ricciarelli E, and Hernández ER

Subjects
Adult, Embryo Implantation drug effects, Embryo Implantation physiology, Embryo Transfer statistics & numerical data, Female, Fertilization, Humans, Pregnancy Outcome, Gonadotropin-Releasing Hormone analogs & derivatives, Gonadotropin-Releasing Hormone antagonists & inhibitors, Gonadotropin-Releasing Hormone therapeutic use, Hormone Antagonists therapeutic use, Luteinizing Hormone therapeutic use, Oocyte Donation, Pregnancy statistics & numerical data
Abstract

Objective: To determine whether LH supplementation improved pregnancy and implantation rates in GnRH antagonist donor cycles., Design: Donors were randomly assigned to a protocol using GnRH antagonist (GnRH-a) alone or GnRH-a + recombinant LH. Analysis of variance, Student's t-test and Fisher's exact test were used where appropriate., Setting: Private clinical setting., Patient(s): Young voluntary donors with antagonist (n = 20) and antagonist + LH (n = 22). Fifty-five patients received oocytes., Intervention(s): Donors received the GnRH-a (Cetrorelix, 0.25 mg/day) alone or in combination with recombinant LH (75 IU/day). Ovulation induction was carried out with recombinant FSH in a step-down protocol. The endometrial tissue of recipient patients was prepared with oral E(2) and P., Main Outcome Measure(s): Pregnancy and implantation rates in a donor program., Result(s): A significant increase in MII oocyte (80% vs. 71%), fertilization rates (83% vs. 71%), G1 embryos (17% vs. 3%), and implantation rates (35% vs. 15%), were found in recipients whose embryos originated from donors receiving GnRH-a + recombinant LH as compared to donors receiving GnRH-a alone. Estradiol levels, pregnancy/transfer and clinical pregnancies were lower (not significant) in donors treated with the GnRH-a alone vs. those receiving the recombinant LH-supplemented GnRH-a., Conclusion(s): The LH supplementation improved the possibilities of gestation for recipients whose embryos originated from GnRH-a-treated donors.

Published
2004
Full Text
View/download PDF

34. Impact of the gonadotropin-releasing hormone antagonist in oocyte donation cycles.

Author

Ricciarelli E, Sanchez M, Martinez M, Andres L, Cuadros J, and Hernandez ER

Subjects
Female, Gonadotropin-Releasing Hormone analogs & derivatives, Humans, Pregnancy, Pregnancy Rate, Triptorelin Pamoate pharmacology, Fertilization in Vitro, Gonadotropin-Releasing Hormone antagonists & inhibitors, Gonadotropin-Releasing Hormone pharmacology, Oocyte Donation
Published
2003
Full Text
View/download PDF

35. The potential relevance of growth hormone to female reproductive physiology and pathophysiology.

Author

Katz E, Ricciarelli E, and Adashi EY

Subjects
Female, Genitalia, Female physiopathology, Gonadotropins physiology, Growth Hormone therapeutic use, Humans, Insulin-Like Growth Factor I physiology, Menopause physiology, Menstrual Cycle physiology, Ovulation drug effects, Polycystic Ovary Syndrome physiopathology, Reference Values, Reproduction, Genitalia, Female physiology, Growth Hormone physiology
Abstract

Objective: To assess possible interfacing between the somatotrophic and reproductive axes., Design: Literature review., Main Outcome Measures: Ovarian growth hormone reception and action., Results: The available literature strongly supports a permissive role for the somatotrophic axis in the reproductive process., Conclusions: Although a role for growth hormone in reproductive biology appears highly likely, its relevance to the process of puberty and to the normal workings of the menstrual cycle, as well as its possible application in reproductive pathology must await further investigation.

Published
1993
Full Text
View/download PDF

36. Insulin-like growth factor receptor gene expression in the rat ovary: divergent regulation of distinct receptor species.

Author

Hernandez ER, Hurwitz A, Botero L, Ricciarelli E, Werner H, Roberts CT Jr, LeRoith D, and Adashi EY

Subjects
Animals, Diethylstilbestrol pharmacology, Female, Follicle Stimulating Hormone pharmacology, Mannosephosphates genetics, Mannosephosphates metabolism, Ovary chemistry, Ovary metabolism, RNA analysis, RNA genetics, Rats, Rats, Inbred Strains, Receptor, Insulin analysis, Receptor, Insulin genetics, Receptor, Insulin metabolism, Receptors, Cell Surface analysis, Receptors, Cell Surface metabolism, Receptors, Somatomedin, Transcription, Genetic drug effects, Gene Expression Regulation genetics, Ovary ultrastructure, Receptors, Cell Surface genetics
Abstract

The intraovarian insulin-like growth factor (IGF) system constitutes a triad composed of ligands, receptors, and binding proteins. Although conventional radioligand receptor assays have documented the presence of specific receptors for insulin and insulin-like peptides in some rat somatic ovarian cell types, the exact cellular localization and hormonal regulation of the receptors in question remain matters of inquiry. To reevaluate the very presence, cellular localization, and hormonal regulation of the IGF receptor gene family in the rat ovary, solution hybridization/RNase protection assays were used wherein ovarian total RNA (20 micrograms) from immature (21-23 days old) rats was hybridized with 32P-labeled type I IGF receptor, type II IGF/mannose-6-phosphate receptor, and insulin receptor riboprobes. Single protected fragments 261 (type I IGF receptor), 500 (type II IGF/mannose-6-phosphate receptor), and 478 (insulin receptor) bases long were evident in whole ovary, granulosa, and theca-interstitial cells. Hypophysectomy of immature rats led to significant (P less than 0.05) albeit variable decrements in the relative (densitometrically quantified) ovarian abundance of transcripts corresponding to the type I IGF (but not insulin or type II IGF/mannose-6-phosphate) receptor. Treatment of immature hypophysectomized rats with FSH (10 micrograms/rat.day x 2.5 days) resulted in a significant (P less than 0.05) increase (4-fold) in transcripts corresponding to the type I IGF receptor in both whole ovarian material and freshly isolated granulosa cells. Similar (3.7-fold) increments (P less than 0.05) were noted after treatment with a diethylstilbestrol-containing sc silastic implant applied for a total of 5 days.(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1991
Full Text
View/download PDF

37. Endocrine- and autocrine-mediated regulation of rat ovarian (theca-interstitial) interleukin-1 beta gene expression: gonadotropin-dependent preovulatory acquisition.

Author

Hurwitz A, Ricciarelli E, Botero L, Rohan RM, Hernandez ER, and Adashi EY

Subjects
Animals, Cells, Cultured, Female, Nucleic Acid Hybridization, Ovary chemistry, RNA, Messenger analysis, Rats, Rats, Inbred Strains, Theca Cells chemistry, Chorionic Gonadotropin pharmacology, Gene Expression Regulation drug effects, Gonadotropins, Equine pharmacology, Interleukin-1 genetics, Ovary metabolism, Theca Cells metabolism
Abstract

We, and others have recently demonstrated the ovary to be a site of interleukin-1 (IL-1) reception and action. Since IL-1 is an established mediator of inflammation and since ovulation may constitute an inflammatory-like reaction, consideration was given to the possibility that IL-1 may play an intermediary role in the ovulatory process. To begin to evaluate the above hypothesis, we have set out to evaluate rat ovarian IL-1 beta gene expression, to determine its cellular localization, and to study its modulation by key endocrine and autocrine regulatory signals. To this end, use was made of a solution hybridization/RNase protection assay in which rat ovarian total RNA (20 micrograms) was hybridized with a [32P]-labeled 272 base rat IL-1 beta antisense riboprobe. To assess rat ovarian IL-1 beta gene expression under in vivo circumstances, use was made of an established experimental model capable of simulating naturally-occurring follicular maturation, ovulation, and corpus luteum formation. Specifically, a single subcutaneous injection of PMSG (15IU/rat) was followed (48h) later by an ovulatory dose (15IU) of human chorionic gonadotropin (hCG). A faint protected fragment 222 bases long corresponding to the IL-1 beta message was detectable in whole ovarian material prior to gonadotropic stimulation. Treatment with PMSG for 48h resulted in a modest, albeit measurable increase in the densitometrically-quantified steady state levels of the ovarian IL-1 beta message. Most striking, however, were the increments noted in the relative abundance of ovarian IL-1 beta transcripts following a 6h exposure to hCG producing a 4 to 5-fold increase (P less than 0.05) over the untreated state at a time point approximately 6h prior to projected follicular rupture. Subsequent evaluation of ovarian IL-1 beta transcripts, 24 and 48h following hCG administration, revealed significant (P less than 0.05) decrements (relative to the 6h peak) to a level comparable to that seen at the conclusion of 48h of treatment with PMSG. Cellular localization studies revealed the gonadotropin-dependent IL-1 beta mRNA to be theca-interstitial cell-exclusive. To assess rat ovarian IL-1 beta gene expression under in vitro circumstances, we have set out to determine whether IL-1 itself may influence the relative level of its own message. Treatment of whole ovarian dispersates with rhIL-1 beta (10ng/ml) for 4 and 24h resulted in a marked (P less than 0.05) time-dependent increase (up to 12-fold) in the relative abundance of IL-1 beta transcripts when compared with untreated controls.(ABSTRACT TRUNCATED AT 400 WORDS)

Published
1991
Full Text
View/download PDF

38. The ovarian expression of the antigonadotropic insulin-like growth factor binding protein-2 is theca-interstitial cell-selective: evidence for hormonal regulation.

Author

Ricciarelli E, Hernandez ER, Hurwitz A, Kokia E, Rosenfeld RG, Schwander J, and Adashi EY

Subjects
Animals, Carrier Proteins genetics, Female, Gene Expression, Hypophysectomy, Insulin-Like Growth Factor Binding Protein 2, Precipitin Tests, Rats, Rats, Inbred Strains, Carrier Proteins metabolism, Gonadotropins antagonists & inhibitors, Hormones physiology, Ovary metabolism, Theca Cells metabolism
Abstract

To begin the process of identification and charactization of rat ovarian insulin-like growth factor binding proteins, we have undertaken to explore the ovarian expression, cellular localization, and hormonal regulation of the insulin-like growth factor binding protein-2 (IGFBP-2) gene for which an antigonadotropic potential has recently been demonstrated. To this end, a solution hybridization/RNase protection assay was employed wherein total ovarian RNA (20 micrograms) from immature (21-23 days old) female rats was hybridized with a [32P]-labeled IGFBP-2 riboprobe. As in liver, a single protected fragment (550 bases long) corresponding to IGFBP-2 transcripts was identified in whole ovarian material. Cellular localization studies revealed the IGFBP-2 gene to be exclusively expressed in the theca-interstitial rather than the granulosa cell compartment. To confirm the cellular distribution of the IGFBP-2 protein, media conditioned by cultured granulosa or theca-interstitial cells were subjected to immunoprecipitation using two IGFBP-2-directed polyclonal antisera. Expectedly, both antibodies (but not non-immune rabbit serum) readily immunoprecipitated the 28 kDa rat IGFBP-2 species generated by hepatic BRL-3A cells. Similarly, both antibodies effectively immunoprecipitated an IGFBP the size of rat IGFBP-2 elaborated by theca-interstitial cells. In contrast, neither antibody immunoprecipitated the 28-29 kDa IGFBP species elaborated by granulosa cells otherwise readily apparent in conventional Western ligand blots. Hypophysectomy resulted in a 3-fold decrease (P less than 0.05) in the relative (densitometrically-quantified) abundance of ovarian IGFBP-2 transcripts, a diametrically opposed effect (P less than 0.05) being noted at the level of the liver. In contrast, treatment of immature hypophysectomized rats with a diethylstilbestrol-containing subcutaneous silastic implant for a total of 5 days resulted in a concordant 3-fold increase (P less than 0.05) in the relative abundance of IGFBP-2 transcripts in both ovary and liver when compared with untreated hypophysectomized controls. Taken together, these findings document rat ovarian IGFPB-2 gene expression to be theca-interstitial (rather than granulosa) cell-selective, and subject to upregulatory control by pituitary principle(s) and/or by estrogens. Although equally estrogen-dependent, hepatic IGFBP-2 gene expression proved constitutive in nature and subject to (diametrically opposed) inhibitory control by (potentially distinct) pituitary principle(s).

Published
1991
Full Text
View/download PDF

39. Ovarian granulosa cell-derived insulin-like growth factor binding proteins: modulatory role of follicle-stimulating hormone.

Author

Adashi EY, Resnick CE, Hurwitz A, Ricciarelli E, Hernandez ER, and Rosenfeld RG

Subjects
Animals, Carrier Proteins antagonists & inhibitors, Chemical Precipitation, Dose-Response Relationship, Drug, Female, Follicle Stimulating Hormone pharmacology, Hypophysectomy, Insulin-Like Growth Factor Binding Proteins, Ovary cytology, Polyethylene Glycols, Rats, Rats, Inbred Strains, Somatomedins metabolism, Carrier Proteins metabolism, Follicle Stimulating Hormone physiology, Granulosa Cells metabolism, Ovary metabolism
Abstract

Recent observations disclosed the multiplicity of granulosa cell-derived high affinity insulin-like growth factor binding proteins (IGFBPs) and revealed the striking ability of high doses of FSH to suppress their constitutive release under both in vitro and in vivo circumstances. It is the objective of this communication to characterize in greater detail the modulatory effect(s) exerted by FSH on the elaboration of IGFBPs by granulosa cells from immature, estrogen-primed rats. The ability of FSH to regulate the elaboration of granulosa cell-derived IGFBPs proved dose-dependent but biphasic in nature. Specifically, FSH concentrations in the range of 1-3 ng/ml applied for 72 h produced a significant (P less than 0.05) increase in polyethylene glycol-precipitable [125I]IGF-I binding activity corresponding to all IGFBP species detectable by ligand blotting. In contrast, treatment with higher concentrations (greater than or equal to 10 ng/ml) of FSH resulted in progressive dose-dependent inhibition of the constitutive release of IGF-I binding activity (80% inhibition at the 100 ng/ml dose level) and the virtual elimination of all detectable IGFBP species. Time-course studies disclosed a significant (P less than 0.05) initial (apparent at the 24-h time point) stimulatory effect of a high dose of FSH (100 ng/ml) corresponding mostly (but not solely) to the single minor (23K) IGFBP band. In contrast, more prolonged exposure to FSH (greater than or equal to 48 h) produced progressive time-dependent decrements in IGF-I binding activity, an effect associated with a decrease in the relative representation of the major band doublet (28-29K), the 23K species being all but eliminated under these experimental circumstances. Hypophysectomy produced significant (P less than 0.05) inhibition of the subsequent in vitro release of granulosa cell-derived precipitable IGF-I binding activity strongly suggesting that (presumptively stimulatory) pituitary principles other than FSH are likely involved in the regulation of granulosa cell IGFBP release and that the trophic influence of these putative agents appears to outweight the potential disinhibition of FSH hormonal action. Taken together, these findings indicate that the pituitary regulation of granulosa cell-derived IGFBPs is complex and is not FSH-exclusive. Our findings further indicate that the ability of FSH to regulate granulosa cell-derived IGFBPs is dose- and time-dependent but biphasic in nature, an effect characterized by an early low-dose stimulatory effect and a late high-dose inhibitory effect.(ABSTRACT TRUNCATED AT 400 WORDS)

Published
1991
Full Text
View/download PDF

40. Infusion of bicarbonate into newborn infants.

Author

DeVore JS and Ricciarelli EA

Subjects
Bicarbonates adverse effects, Cerebral Hemorrhage chemically induced, Humans, Infant, Newborn, Acidosis drug therapy, Bicarbonates therapeutic use, Infant, Newborn, Diseases drug therapy
Published
1976
Full Text
View/download PDF

41. Opioids and obstetrics.

Author

Ricciarelli EA, Gutsche BB, and Smith TC

Subjects
Asphyxia Neonatorum chemically induced, Female, Fetus drug effects, Humans, Infant, Newborn, Infant, Newborn, Diseases chemically induced, Maternal-Fetal Exchange, Meperidine pharmacology, Morphine pharmacology, Nalorphine pharmacology, Naloxone pharmacology, Narcotic Antagonists pharmacology, Narcotics adverse effects, Narcotics analysis, Oxymorphone, Pregnancy, Substance-Related Disorders complications, Analgesia adverse effects, Analgesics pharmacology, Anesthesia, Obstetrical, Narcotics pharmacology
Published
1974
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results